The U.S. Food and Drug Administration launched a new priority review voucher program intended to incentivize drug developers addressing national health priorities by offering accelerated review timelines reduced from the standard 10-12 months to as little as one to two months. This initiative aligns with broader efforts to boost innovative cures, domestic drug production, and respond to unmet health crises, although the agency continues to experience staffing shortages causing missed approval deadlines for certain therapies. Consolidation plans within FDA resource groups aim to improve efficiency but raise concerns about review delays and impacts on drug developers.